AIM movers: Thalia Therapeutics acquisition and Velocity Composites second half hit by business mix Thalia Therapeutics (LON: THAT), formerly N4 Pharma, is acquiring Sanmirna Therapeutics Inc, which is developing miRisten for the treatment of…
AIM movers: WH Ireland selling wealth management business and Nuvec success for N4 Pharma N4 Pharma (LON: N4P) along with its partner SRI has achieved precision targeting of the Nuvec gene delivery system. A…
N4 Pharma shares rise on lung cancer cell targeting update N4 Pharma shares rose on Monday after announcing an update on its collaborations with the research institute SRI to test…
AIM movers: Mkango Resources intends to spin off assets in Nasdaq shell and RBG terminates Ian Rosenblatt consultancy Former Avacta boss Dr Alastair Smith has become a non-executive director of gene delivery technology developer N4 Pharma (LON: N4P).…